

BIBLIOGRAPHY

Book Chapters\Invited Reviews

1. Struewing JP. *BRCA1* in special populations. *Breast Dis* 1998; 10:71-5.
2. Jacobs IJ, Shepherd JH, Oram DH, et al. "The penetrance of *BRCA1/2* mutations" in Ovarian Cancer. Oxford: Oxford University Press, 2002:427.
3. Struewing JP. Genomic approaches to identifying breast cancer susceptibility factors. *Breast Dis* 2004;19:3-9.

Journal Articles

1. Ash SR, Struewing JP. Clinical trials of column disc peritoneal catheter (Lifecath, TM). *Peritoneal Dialysis Bull* 1983;3:77-80.
2. Epstein RS, Struewing JP, Sharkness CM, Lefkowitz A, Cadigan DA, Flynn JPG, Kessler II. Secular changes in case mix of SCI patients at Montebello. *Maryland Med J* 1988;37:291-6.
3. Epstein RS, Lefkowitz A, Sharkness CM, Struewing JP, Cadigan DA, Kessler II, Flynn JPG. Predictors of rehabilitation outcome among patients with SCI. *Maryland Med J* 1989;38:489-92.
4. Abdel-Wahab MF, Esmat G, Narooz SI, Yosery A, Struewing JP, Strickland GT. Sonographic studies of schoolchildren in a village endemic for *Schistosoma mansoni*. *Trans Royal Soc Trop Med Hygiene* 1990;84:69-73.
5. Struewing JP, Gray GC. An epidemic of respiratory complaints exacerbated by mass psychogenic illness in a military recruit population. *Am J Epidemiol* 1990;132:1120-9.
6. Gray GC, Escamilla J, Hyams KC, Struewing JP, Kaplan EL, Tupponce AK. Hyperendemic *Streptococcus pyogenes* infection despite prophylaxis with penicillin G benzathine. *N Engl J Med* 1991;325:92-7.
7. Gray GC, Struewing JP, Clever GC, Kulhenkamp JF. Worst California measles epidemic in twenty-five years. *Navy Med* 1991;82(4):23-5.
8. Struewing JP, Pape DM, Snow DA. Improving colorectal cancer screening in a medical residents' primary care clinic. *Am J Prev Med* 1991;7:75-81.
9. Fujikawa J, Struewing JP, Hyams KC, Kaplan EL, Tupponce AK, Gray GC. Oral erythromycin prophylaxis against *Streptococcus pyogenes* infection in penicillin-allergic military recruits: a randomized clinical trial. *J Infect Dis* 1992;166:162-5.
10. Bassily S, Strickland GT, Abdel-Wahab MF, Esmat GE, Narooz S, el-Masry NA, Constantine NT, Struewing JP. Efficacy of hepatitis B vaccination in primary school children from a village endemic for *Schistosoma mansoni*. *J Infect Dis* 1992;166:265-8.
11. Hyams KC, Struewing JP, Gray GC. Seroprevalence of hepatitis A, B, and C in a United States military recruit population. *Military Med* 1992;157:579-82.
12. Trump, DH, Hyams KC, Cross ER, Struewing JP. Tuberculosis infection among young adults entering the US Navy in 1990. *Arch Intern Med* 1993; 153:211-6.
13. Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian cancer. *Cancer* 1993;71:566-72.
14. Gray GC, Struewing JP, Escamilla J, Hyams KC, Escamilla J, Tupponce AK, Kaplan EL. Interpreting a single anti-streptolysin O test: a comparison of the "upper limit of normal" and likelihood ratio methods. *J Clin Epidemiol* 1993;46:1181-5.

15. Musher DM, Groover JE, Rowland JM, Watson DA, Struewing JP, Baughn RE, Mufson MA. Antibody to capsular polysaccharides of *Streptococcus pneumoniae*: prevalence, persistence, and response to revaccination. *Clin Infect Dis* 1993;17:66-73.
16. Struewing JP, Hyams KC, Tueller JE, Gray GC. The risk of measles, mumps, and varicella among young adults: a serosurvey of US Navy and Marine Corps recruits. *Am J Public Health* 1993;83:1717-20.
17. Smith SA, DiCioccio RA, Struewing JP, Easton DF, Gallion HH, Mazoyer S, Johansson B, Steichen-Gersdorf E, Stratton M, Ford D, Marshall G, Piver MS, Ponder BA. Localisation of the breast-ovarian cancer susceptibility gene (BRCA1) on 17q12-21 to an interval of \leq 1cM. *Genes, Chromosomes Cancer* 1994;10:71-6.
18. Hussussian CJ*, Struewing JP*, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH Jr., Tucker MA, Dracopoli NC. Germline p16 mutations in familial melanoma. *Nat Genet* 1994;8:15-21. (* contributed equally to work)
19. Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, Ponder BAJ, Weber BL, Garber JE, Birch JM, Cornelis RS, Kelsell DP, Spurr NK, Smyth E, Haites N, Sobol H, Bignon YJ, Chang-Claude J, Hamman U, Lindblom A, Borg A, Piver MS, Gallion HH, Struewing JP, Whittemore A, Tonin P, Goldgar DE, Easton DF, and the Breast Cancer Linkage Consortium. An evaluation of genetic heterogeneity in 145 Breast-Ovarian Cancer Families. *Am J Hum Genet* 1995;56:254-64.
20. Brody LC, Abel KJ, Castilla LH, Couch FJ, McKinley DR, Yin G, Ho PP, Merajver S, Chandrasekharappa SC, Xu J, Cole JL, Struewing JP, Valdes JM, Collins FS, Weber BL. Construction of transcription map surrounding the *BRCA1* locus of human chromosome 17. *Genomics* 1995;25:238-47.
21. Struewing JP, Lerman C, Kase RG, Giambaresi TR, Tucker MA. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. *Cancer Epidemiol Biomarkers Prev* 1995;4:169-73.
22. Struewing JP, Watson P, Easton DF, Ponder BAJ, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. *Monogr Natl Cancer Inst* 1995;17:33-5.
23. Struewing JP, Brody LC, Erdos MR, Kase RG, Giambaresi TR, Smith SA, Collins FS, Tucker MA. Detection of eight *BRCA1* mutations in ten breast/ovarian cancer families, including one family with male breast cancer. *Am J Hum Genet* 1995;57:1-7.
24. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC. The carrier frequency of the *BRCA1* 185delAG mutation is approximately 1% in Ashkenazi Jewish individuals. *Nat Genet* 1995;11:198-200.
25. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr, Tucker MA. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16(INK4) mutations. *New Engl J Med* 1995;333:970-4.
26. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offitt K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop R, Kelsel D, Solomon E, Weber B, Couch F, Struewing J, Tonin P, Durocher F, Narod S, Skolnick MH, Lenoir G, Serova O, Ponder B, Stoppa-Lyonnet S, Easton D, Kinc MC, Goldgar DE. Haplotype and phenotype analysis of six recurrent *BRCA1* mutations in 61 families: results of an international study. *Am J Hum Genet* 1996;58:271-80.
27. Struewing JP, Tarone RE, Brody LC, Li FP, Boice JD, Jr. BRCA1 mutations in young women with breast cancer. *Lancet* 1996; 347:1493.
28. Smith KL, Wilson M, Hightower AW, Kelley PW, Struewing JP, Juranek DD, McAuley JB. Prevalence of *Toxoplasma gondii* antibodies in U.S. military recruits in 1989: comparison with data published in 1965. *Clin Infect Dis* 1996; 23:1182-3.
29. Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos

- J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Garber JE, et al. Frequency of recurrent *BRCA1* and *BRCA2* mutations in Ashkenazi Jewish breast cancer families. *Nat Med* 1996; 2:1179-83.
30. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K. The carrier frequency of the *BRCA2* 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. *Nat Genet* 1996; 14:188-90.
 31. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of *BRCA1* and *BRCA2* among Ashkenazi Jews. *New Engl J Med* 1997; 336:1401-8.
 32. Abbaszadegan MR, Struewing JP, Brown KM, Snider JV, Goodsaid F, Gore-Langton R, Hughes MR. Automated detection of prevalent mutations in *BRCA1* and *BRCA2* genes, using a fluorogenic PCR allelic discrimination assay. *Genet Testing* 1997; 1:171-180.
 33. Emmert-Buck MR, Weiss RA, DiFranco EM, Aznavoorian S, Linehan WM, Vocke C, Chuaqui F, Merino MJ, Liotta LA, Zhuang Z, Struewing JP. Allelic loss on chromosome 8p in *BRCA1* mutation positive breast/ovarian cancers. *Breast J* 1998;4:9-12.
 34. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, et al. Genetic heterogeneity and penetrance analysis of the *BRCA1* and *BRCA2* genes in breast cancer families. The Breast Cancer Linkage Consortium. *Am J Hum Genet* 1998; 62:676-89.
 35. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BAJ, Ford D, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JGM, Devilee P, Cornelisse CJ, Lasset C, Lenoir G, Barkardottir RB, Egilsson V, Hamann U, Chang-Claude J, Sobol H, Weber B, Stratton MR, Easton DF. Multifactorial analysis of differences between sporadic breast cancers and cancers involving *BRCA1* and *BRCA2* mutations. *J Natl Cancer Inst* 1998; 90:1138-1145.
 36. Woodage T, King SM, Wacholder S, Hartge P, Struewing JP, McAdams M, Laken SJ, Tucker MA, Brody LC. The *APC1307K* allele and cancer risk in a community-based study of Ashkenazi Jews. *Nat Genet* 1998; 20:62-5.
 37. Wacholder S, Hartge P, Struewing JP, Pee D, McAdams M, Brody L, Tucker M. The kin-cohort study for estimating penetrance. *Am J Epidemiol* 1998; 148:623-630.
 38. Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjord JE. Population-based study of risk of breast cancer in carriers of *BRCA2* mutation. *Lancet* 1998; 352:1337-1339.
 39. Lee JS, Wacholder S, Struewing JP, McAdams M, Pee D, Brody LC, Tucker MA, Hartge P. Survival after breast cancer in Ashkenazi Jewish *BRCA1* and *BRCA2* mutation carriers. *J Natl Cancer Inst* 1999; 91:259-63.
 40. Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common *BRCA1* and *BRCA2* mutations among Ashkenazi Jews. *Am J Hum Genet* 1999; 64:963-970.
 41. Sherman ME, Lee JS, Burks RT, Struewing JP, Kurman RJ, Hartge P. Histopathologic features of ovaries at increased risk for carcinoma: a case-control analysis. *Int J Gynecol Pathol* 1999; 18:151-7.
 42. Kaufman DJ, Struewing J. Re: Effect of *BRCA1* and *BRCA2* on the association between breast cancer risk and family history. *J Natl Cancer Inst* 1999; 91:1250-1251.
 43. Struewing JP, Coriaty ZM, Ron E, Livoff A, Konichezky M, Cohen P, Resnick MB, Lifzchiz-Mercerl B, Lew S, Iscovich J. Founder *BRCA1/2* mutations among male patients with breast cancer in Israel.

Am J Hum Genet 1999;65:1800-1802.

44. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, Venter D, Freeman A, Antoniou A, McGuffog L, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BAJ, Futreal PA, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Bishop DT, Klijn JGM, Devilee P, Cornelisse CJ, Lasset C, Lenoir G, Barkardottir RB, Egilsson V, Hamann U, Chang-Claude J, Sobol H, Weber B, Easton DF, Stratton MR. The pathology of familial breast cancer: Histological features of cancers in families not attributable to mutations in *BRCA1* or *BRCA2*. *Clin Cancer Res* 2000; 6:782-789.
45. Biesecker BB, Ishibe N, Hadley DW, Giambarrresi TR, Kase RG, Lerman C, Struewing JP. Psychosocial factors predicting *BRCA1/BRCA2* testing decisions in members of hereditary breast and ovarian cancer families. *Am J Med Genet* 2000;93:257-63.
46. Ciotti P, Struewing JP, Mantelli M, Chompret A, Avril MF, Santi PL, Tucker MA, Bianchi-Scarra G, Bressac-De Paillerets B, Goldstein AM. A single genetic origin for the G101W *CDKN2A* mutation in 20 melanoma-prone families. *Am J Hum Genet* 2000; 67:311-9.
47. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in U.S. melanoma-prone families with *CDKN2A* and *CDK4* mutations. *J Natl Cancer Inst* 2000; 92:1006-10.
48. Fishman A, Dekel E, Chetrit A, Lerner-Geva L, Bar-Am A, Beck D, Beller U, Ben-Baruch G, Piura B, Friedman E, Struewing JP, Modan B. Patients with double primary tumors in the breast and ovary - Clinical characteristics and *BRCA1-2* mutations status. *Gynecologic Oncol* 2000; 79:74-8.
49. Goldstein AM, Liu L, Shennan MG, Hogg D, Tucker MA, Struewing JP. A common founder for the V126D *CDKN2A* mutation in seven North American melanoma-prone families. *Br J Cancer* 2001; 85:527-30.
50. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, Ben-Baruch G, Fishman A, Menczer J, Ebbers SM, Tucker MA, Wacholder S, Struewing JP, Friedman E, Piura B. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a *BRCA1* or *BRCA2* mutation. *N Engl J Med* 2001; 345:235-40.
51. Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M, Levavi H, Pierce H, Chetrit A, Yechezkel GH, Chenevix-Trench G, Offit K, Godwin AK, Struewing JP. A single nucleotide polymorphism in the 5' untranslated region of *RAD51* and risk of cancer among *BRCA1/2* mutation carriers. *Cancer Epidemiol Biomarkers Prev* 2001; 10:955-60.
52. Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U, Ben-Baruch G, Fishman A, Levavi H, Lubin F, Menczer J, Piura B, Struewing JP, Modan B. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. *J Clin Oncol* 2002; 20:463-6.
53. Pfeiffer RM, Rutter JL, Gail MH, Struewing J, Gastwirth JL. Efficiency of DNA pooling to estimate joint allele frequencies and measure linkage disequilibrium. *Genet Epidemiol* 2002; 22:94-102.
54. Hartge P, Chatterjee N, Wacholder S, Brody LC, Tucker MA, Struewing JP. Breast cancer risk in Ashkenazi *BRCA1/2* mutation carriers: Effects of reproductive history. *Epidemiology* 2002; 13:255-261.
55. Tucker MA, Fraser MC, Goldstein AM, Struewing JP, King MA, Crawford JT, Chiazzese EA, Zametkin DP, Fontaine LS, Clark WH, Jr. A natural history of melanomas and dysplastic nevi. *Cancer* 2002; 94:3192-209.
56. Zhang J, Rowe WL, Struewing JP, Buetow KH. HapScope: a software system for automated and visual analysis of functionally annotated haplotypes. *Nucleic Acids Res* 2002; 30:5213-21.

57. Menczer J, Chetrit A, Barda G, Lubin F, Fishler Y, Altaras M, Levavi H, Struewing JP, Sadetzki S, Modan B. Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women. *Gynecol Oncol* 2003; 88:58-61.
58. Hirsh-Yechezkel G, Chetrit A, Lubin F, Friedman E, Peretz T, Gershoni R, Rizel S, Struewing JP, Modan B. Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel. *Gynecol Oncol* 2003; 89:494-8.
59. Rutter JL, Smith AM, Davila MR, Sigurdson AJ, Giusti RM, Pineda MA, Doody MM, Tucker MA, Greene MH, Zhang J, Struewing JP. Mutational analysis of the *BRCA1*-interacting genes *ZNF350/ZBRK1* and *BRIP1/BACH1* among *BRCA1* and *BRCA2*-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. *Hum Mutat* 2003; 22:121-8.
60. Rutter JL, Wacholder S, Chetrit A, Lubin F, Menczer J, Ebbers S, Tucker MA, Struewing JP, Hartge P. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. *J Natl Cancer Inst* 2003; 95:1072-8.
61. Rutter JL, Goldstein AM, Davila MR, Tucker MA, Struewing JP. *CDKN2A* point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF. *Oncogene* 2003; 22:4444-8.
62. Hauptmann M, Sigurdson AJ, Chatterjee N, Rutter JL, Hill DA, Doody MM, Struewing JP. Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. *J Natl Cancer Inst* 2003; 95:1251-2.
63. Giusti RM, Rutter JL, Duray PH, Freedman LS, Konichezky M, Fisher-Fischbein J, Greene MH, Maslansky B, Fischbein A, Gruber SB, Rennert G, Ronchetti RD, Hewitt SM, Struewing JP, Iscovich J. A twofold increase in *BRCA* mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. *J Med Genet* 2003;40:787-92.
64. Kaufman DJ, Beaty TH, Struewing JP. Segregation analysis of 231 Ashkenazi Jewish families for evidence of additional breast cancer susceptibility genes. *Cancer Epidemiol Biomarkers Prev* 2003; 12:1045-52.
65. Rutter JL, Chatterjee N, Wacholder S, Struewing J. The HER2 I655V polymorphism and breast cancer risk in Ashkenazim. *Epidemiology* 2003; 14:694-700.
66. Haque KA, Pfeiffer RM, Beerman MB, Struewing JP, Chanock SJ, Bergen AW. Performance of high-throughput DNA quantification methods. *BMC Biotechnol* 2003; 3:20.
67. Baccarelli A, Calista D, Minghetti P, Marinelli B, Albetti B, Tseng T, Hedayati M, Grossman L, Landi G, Struewing JP, Landi MT. *XPD* gene polymorphism and host characteristics in the association with cutaneous malignant melanoma risk. *Br J Cancer* 2004; 90:497-502.
68. Sigurdson AJ, Hauptmann M, Chatterjee N, Alexander BH, Doody MM, Rutter JL, Struewing JP. Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, *BRCA1* interacting and growth factor genes. *BMC Cancer* 2004; 4:9.
69. Struewing JP, Hartge P, Wacholder S, Tucker MA, Greene MH. *BRCA1* and sex ratio. *Eur J Hum Genet* 2004 ;12:663-7.
70. Goldstein AM, Struewing JP, Fraser MC, Smith MW, Tucker MA. Prospective risk of cancer in *CDKN2A* germline mutation carriers. *J Med Genet* 2004;41:421-4.
71. McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP. *BRCA1/2* testing in hereditary breast and ovarian cancer families: Effectiveness of problem-solving training as a counseling intervention. *Am J Med Genet* 2004; 130A:221-7.

72. Mateus Pereira LH, Sigurdson AJ, Doody MM, Pineda MA, Alexander BH, Greene MH, Struewing JP. *CHEK2*:1100delC and female breast cancer in the United States. *Int J Cancer* 2004; 112:541-3.
73. Rutter JL, Bromley CM, Goldstein AM, Elder DE, Holly EA, Guerry Dt, Hartge P, Struewing JP, Hogg D, Halpern A, Sagebiel RW, Tucker MA. Heterogeneity of risk for melanoma and pancreatic and digestive malignancies. *Cancer* 2004; 101:2809-16.
74. Wacholder S, Struewing JP, Hartge P, Greene MH, Tucker MA. Breast cancer risks for *BRCA1/2* carriers (letter). *Science* 2004; 306:2187-91; author reply 2187-91.
75. McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP. *BRCA1/2* testing in hereditary breast and ovarian cancer families II: impact on relationships. *Am J Med Genet A* 2005;133:165-9.
76. Sigurdson AJ, Hauptmann M, Alexander BH, Doody MM, Thomas CB, Struewing JP, Jones IM. DNA damage among thyroid cancer and multiple cancer cases, controls, and long-lived individuals. *Mutat Res* 2005;586:173-88.
77. Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of *BRCA1* mutation carriers. *J Clin Oncol* 2005;23:8629-8635.
78. Ellis NA, Kirchhoff T, Mitra N, Ye TZ, Chuai S, Huang H, Nafa K, Norton L, Neuhausen S, Gordon D, Struewing JP, Narod S, Offit K. Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping. *Genet Epidemiol* 2006;30:48-61.
79. Struewing JP, Pineda MA, Sherman ME, Lissowska J, Brinton LA, Peplonska B, Bardin-Mikolajczak A, Garcia-Closas M. Skewed X chromosome inactivation and early-onset breast cancer. *J Med Genet* 2006;43:48-53.
80. Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR, Smith PL, Greene MH, Simard J, Plourde M, Southey MC, Godwin AK, Beck J, Miron A, Daly MB, Santella RM, Hopper JL, John EM, Andrulis IL, Durocher F, Struewing JP, Easton DF, Chenevix-Trench G. The *AIB1* polyglutamine repeat does not modify breast cancer risk in *BRCA1* and *BRCA2* mutation carriers. *Cancer Epidemiol Biomarkers Prev* 2006;15:76-79.
81. Garcia-Closas M, Egan KM, Newcomb PA, Brinton LA, Chanock S, Welch R, Lissowska J, Peplonska B, Szeszenia-Dąbrowska N, Zatonski W, Bardin-Mikolajczak A, Struewing JP. Polymorphisms in DNA double strand break repair genes and risk of breast cancer: two population-based studies in the USA and Poland, and meta-analyses. *Hum Genet* 2006;119:376-88.
82. Stredrick DL, Garcia-Closas M, Pineda MA, Bhatti P, Alexander BH, Doody MM, Lissowska J, Peplonska B, Brinton LA, Chanock SJ, Struewing JP, Sigurdson AJ. The *ATM* missense mutation Ser49Cys (c.146C>G) and risk of breast cancer. *Hum Mutat* 2006;27:538-44.

June 2006